BioWorld43 秒
Oculis presents 'groundbreaking' data in optic neuritis with OCS-05
Ophthalmic diseases specialist Oculis Holding AG announced positive phase II data showing its serum-glucose corticoid ...
Oculis Trial Shows Potential for Optical Neuroprotective Therapy
By Karen Roman Oculis Holding AG (Nasdaq: OCS) said Phase 2 of its neuroprotective candidate OCS-05 met key endpoints of ...